Quarterly report pursuant to Section 13 or 15(d)

Business Combinations - Summary of Fair Value of Purchase Price Consideration (Details)

v3.22.1
Business Combinations - Summary of Fair Value of Purchase Price Consideration (Details) - USD ($)
$ in Thousands
Mar. 01, 2022
Sep. 14, 2021
March 2022 Acquisition [Member]    
Business Acquisition [Line Items]    
Cash consideration at closing $ 1,500  
Equity consideration at closing 1,929  
Deferred consideration 2,707  
Acquired cash 684  
Settlement of pre-existing receivable (976)  
Total $ 5,844  
Pandologic Ltd [Member]    
Business Acquisition [Line Items]    
Cash consideration at closing   $ 58,733
Equity consideration at closing   31,500
Net working capital adjustment   5,818
Total   122,451
Pandologic Ltd [Member] | Contingent Consideration    
Business Acquisition [Line Items]    
Contingent earnout   $ 26,400